Exosome therapy

Human data exist, but not for healthspan. The largest synthesis, a 2025 systematic review and meta-analysis of 39 human clinical studies in Aesthetic Surgery Journal, reports roughly 20% wrinkle reduction, 15-23% gains in pigmentation, elasticity and texture, and 18-24% improvements in hair density and thickness. Its own limitations are decisive: most included studies were open-label or single-arm, Cochrane ROB2 risk-of-bias assessment was "often not feasible", sample sizes were small and follow-up ran only 6-12 weeks. Every endpoint was surface dermatologic or trichologic. There are no systemic outcomes, no biomarkers of ageing, no organ-function or mortality data, and no controlled human trial of exosomes for any healthspan endpoint in either market. Systemic or IV exosome use for longevity is supported by mechanism and animal work only. Product characterisation is a second problem: "exosome" preparations are not standardised between suppliers, dose is not expressed in any comparable unit, and stem cell culture supernatant is a different and less defined material again. Safety is not neutral. A 2025 case series documents four women with persistent erythema, granulomatous nodules and permanent scarring after intradermal injection of cosmetic-grade exosome formulations, none of whom fully resolved despite steroids, laser and surgery. No exosome product holds marketing approval as a medicine in Australia, Singapore, the US or the EU. This should be presented as an aesthetic adjunct with early-stage cosmetic evidence, not as a systemic longevity protocol.

What it is

Plain-language explainer

Categories

Common questions

What is Exosome therapy?

Human data exist, but not for healthspan. The largest synthesis, a 2025 systematic review and meta-analysis of 39 human clinical studies in Aesthetic Surgery Journal, reports roughly 20% wrinkle reduction, 15-23% gains in pigmentation, elasticity and texture, and 18-24% improvements in hair density and thickness. Its own limitations are decisive: most included studies were open-label or single-arm, Cochrane ROB2 risk-of-bias assessment was "often not feasible", sample sizes were small and follow-up ran only 6-12 weeks. Every endpoint was surface dermatologic or trichologic. There are no systemic outcomes, no biomarkers of ageing, no organ-function or mortality data, and no controlled human trial of exosomes for any healthspan endpoint in either market. Systemic or IV exosome use for longevity is supported by mechanism and animal work only. Product characterisation is a second problem: "exosome" preparations are not standardised between suppliers, dose is not expressed in any comparable unit, and stem cell culture supernatant is a different and less defined material again. Safety is not neutral. A 2025 case series documents four women with persistent erythema, granulomatous nodules and permanent scarring after intradermal injection of cosmetic-grade exosome formulations, none of whom fully resolved despite steroids, laser and surgery. No exosome product holds marketing approval as a medicine in Australia, Singapore, the US or the EU. This should be presented as an aesthetic adjunct with early-stage cosmetic evidence, not as a systemic longevity protocol.

How strong is the evidence for Exosome therapy?

Commercial. It is offered and sold, which is a statement about availability, not about efficacy.

Is Exosome therapy approved in Singapore?

variis has no Health Sciences Authority position on file for Exosome therapy. Absence of a recorded position is not approval.

Is Exosome therapy approved in Australia?

Therapeutic Goods Administration position on record: Not TGA-approved. Exosome and extracellular vesicle products fall under the TGA biologicals framework of the Therapeutic Goods Act 1989, and peer-reviewed analysis of the Australian regulatory landscape (Extracellular Vesicles and Circulating Nucleic Acids, 2025) confirms that of the 49 biological products on the ARTG as of April 2025, none are EV medicines. EVs from non-pluripotent stem cells would most likely be Class 3 biologicals, requiring a full non-clinical and clinical dossier. Lawful access to an unapproved exosome product is therefore only via a clinical trial, the Special Access Scheme (Category B) or the Authorised Prescriber scheme under s32CM, none of which are PBS-subsidised. Cosmetic-style topical add-on use as sold on aesthetic and longevity clinic menus sits outside any ARTG approval. Not verified: whether the TGA has issued exosome-specific enforcement action or a public advisory.. An evidence grade and a regulatory approval are different questions.

Which clinics offer Exosome therapy?

2 clinics in the variis directory across Singapore and Australia have Exosome therapy on record. Each is listed on this page with its own sourced profile.

What else is Exosome therapy called?

Also known as Exosomes, Extracellular vesicles (EVs), Stem cell derived exosomes, Mesenchymal stem cell (MSC) exosomes, Stem cell culture supernatant, Conditioned media / secretome.